Understanding Holding vs Bridging Therapy for CAR T in Multiple Myeloma - Targeted Oncology
Understanding Holding vs Bridging Therapy for CAR T in Multiple Myeloma Targeted Oncology
Multiple Myeloma News
Study Identifies Why Multiple Myeloma May Return After Immunotherapy - Cure Today
Study Identifies Why Multiple Myeloma May Return After Immunotherapy Cure Today
Multiple myeloma cells adapt after immunotherapy, helping explain why many patients relapse - Medical Xpress
Multiple myeloma cells adapt after immunotherapy, helping explain why many patients relapse Medical Xpress
Balancing Early Intervention in Smoldering Multiple Myeloma - OncLive
Balancing Early Intervention in Smoldering Multiple Myeloma OncLive
A Home Away from Home: Randy’s Multiple Myeloma Story - University of Missouri Health Care
A Home Away from Home: Randy’s Multiple Myeloma Story University of Missouri Health Care
Subgroup Insights in Early Relapse Multiple Myeloma - CancerNetwork
Subgroup Insights in Early Relapse Multiple Myeloma CancerNetwork
NICE expands access to Blenrep® for multiple myeloma patients - Oncology Central
NICE expands access to Blenrep® for multiple myeloma patients Oncology Central
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD - Pharmaceutical Executive
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD Pharmaceutical Executive
Multiple myeloma drug Blenrep backed for wider NHS use - pharmaphorum
Multiple myeloma drug Blenrep backed for wider NHS use pharmaphorum
Talquetamab Resistance in Multiple Myeloma: New Study Reveals How GPRC5D Antigen Escape Drives Treatment Failure - Pharmacy Times
Talquetamab Resistance in Multiple Myeloma: New Study Reveals How GPRC5D Antigen Escape Drives Treatment Failure Pharmacy Times
NICE Backs Belantamab Mafodotin for Relapsed Myeloma - Medscape
NICE Backs Belantamab Mafodotin for Relapsed Myeloma Medscape
IRAKLIA Trial Validates Subcutaneous Isatuximab in Multiple Myeloma - Targeted Oncology
IRAKLIA Trial Validates Subcutaneous Isatuximab in Multiple Myeloma Targeted Oncology
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7 - Nature
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7 Nature
AQUILA Trial Findings in Smoldering Multiple Myeloma - OncLive
AQUILA Trial Findings in Smoldering Multiple Myeloma OncLive
Safety Considerations for Bispecific Antibodies in Multiple Myeloma - CancerNetwork
Safety Considerations for Bispecific Antibodies in Multiple Myeloma CancerNetwork
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly - Nature
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly Nature
Identifying Appropriate Candidates for Cellular Therapy in Multiple Myeloma - OncLive
Identifying Appropriate Candidates for Cellular Therapy in Multiple Myeloma OncLive
Applying MajesTEC-3 Findings to a Patient With Early Relapsed Myeloma - Targeted Oncology
Applying MajesTEC-3 Findings to a Patient With Early Relapsed Myeloma Targeted Oncology
Referral Timing and Access to Advanced Therapies in Multiple Myeloma - OncLive
Referral Timing and Access to Advanced Therapies in Multiple Myeloma OncLive
Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center
Multiple Myeloma: Improved Prognosis With the Latest Treatments Memorial Sloan Kettering Cancer Center
Dana-Farber to Present 50+ Studies at AACR 2026 - Mirage News
Dana-Farber to Present 50+ Studies at AACR 2026 Mirage News
Why Collaborative Care Is Changing What It Means to Live With Multiple Myeloma - University of Miami
Why Collaborative Care Is Changing What It Means to Live With Multiple Myeloma University of Miami
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease - Sanofi
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease Sanofi
Bristol Myers Squibb evolves and expands multiple myeloma programme - PMLiVE
Bristol Myers Squibb evolves and expands multiple myeloma programme PMLiVE
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial - University of Miami
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial University of Miami
Community-Based Care Delivery and Operational Considerations in R/R MM - Targeted Oncology
Community-Based Care Delivery and Operational Considerations in R/R MM Targeted Oncology
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts - Memorial Sloan Kettering Cancer Center
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts Memorial Sloan Kettering Cancer Center
Diagnosis, risk stratification and management of smouldering multiple myeloma - Nature
Diagnosis, risk stratification and management of smouldering multiple myeloma Nature
Blood Cancer Patients and Their Supporters Cycle Across - GlobeNewswire
Blood Cancer Patients and Their Supporters Cycle Across GlobeNewswire
Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature
Enhanced dynamic risk stratification of smoldering multiple myeloma Nature
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma The University of Alabama at Birmingham
"My company makes the medication that helped me fight multiple myeloma" - Johnson & Johnson
"My company makes the medication that helped me fight multiple myeloma" Johnson & Johnson
Committed Care Team Explores Every Avenue Possible to Treat Young Woman's Multiple Myeloma - Mass General Brigham
Committed Care Team Explores Every Avenue Possible to Treat Young Woman's Multiple Myeloma Mass General Brigham
MajesTEC-3 Trial Results and Earlier-Line Treatment Evidence - Targeted Oncology
MajesTEC-3 Trial Results and Earlier-Line Treatment Evidence Targeted Oncology
Current Bispecific Landscape and Patient Eligibility Considerations - Targeted Oncology
Current Bispecific Landscape and Patient Eligibility Considerations Targeted Oncology
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials - Nature
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials Nature
Established cancer drug gives multiple myeloma immunotherapy new lease of life - Oncology Central
Established cancer drug gives multiple myeloma immunotherapy new lease of life Oncology Central
NICE recommendation expands NHS access to multiple myeloma treatment - National Health Executive
NICE recommendation expands NHS access to multiple myeloma treatment National Health Executive
Minimal Residual Disease Testing in Multiple Myeloma - ASCO Daily News
Minimal Residual Disease Testing in Multiple Myeloma ASCO Daily News
Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities - Journal of Health Economics and Outcomes Research
Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities Journal of Health Economics and Outcomes Research